Calls Purchased on Cleveland Biolabs (CBLI)

Shares of Cleveland Biolabs Inc.

ended the session higher by 2.40%, trading at $3.84. The stock has been drifting lower over the past six months, but has managed to regain the 50-day and 200-day moving averages in today’s trading. Options traders were picking up calls on the name as well. Though the action consisted primarily of small lots, call volume was running at 6x the daily average with over 81% of all calls traded being purchases on the offer. Traders were focusing on the $2.50 and $5.00 strikes in multiple months. Cleveland BioLabs, Inc., incorporated on June 5 2003, is a biotechnology company focused on developing biodefense, tissue protection and cancer treatment drugs based on the concept of modulation of cell death for therapeutic benefit.